Positive FDA feedback on NDA submission process
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Appendix 4E - Summary of Results
- Appendix 4C - December 2019 Quarter
- Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
- NDA Clinical Briefing Package Submitted to the US FDA
- Zircon P3 IND submitted to US FDA
Later from Telix Pharmaceuticals
- Telix and partners receive 500k CRC research grant
- Telix completes acquisition of licensed production facility
- Commercial Distribution Agmt for Prostate Cancer Diagnostic
- Appendix 4C and Activity Report March 2020 quarter
- S&P DJI Announces June 2020 Quarterly Rebalance
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals